AMBU-B.CO - Ambu A/S
| Previous close | 107.50 |
| Open | 108.30 |
| Bid | 110.30 x 0 |
| Ask | 110.30 x 0 |
| Day's range | 108.25 - 111.20 |
| 52-week range | 61.26 - 121.65 |
| Volume | |
| Avg. volume | 765,333 |
| Market cap | 29.703B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 15 Dec 2021 |
| 1y target est | N/A |
- Globe Newswire
INTERIM REPORT FOR Q2 2022/23 AND THE HALF-YEAR
Ambu posts 4% organic revenue growth for the second quarter of 2022/23, in line with expectations. The quarter was driven by continued strong growth in urology and ENT, offset by pulmonology and Anaesthesia. Financial guidance is maintained for the fiscal year 2022/23, with organic revenue growth at 5-8% and EBIT margin before special items at 3-5%. “In the second quarter, Ambu delivers 4% organic revenue growth and 3.9% EBIT margin, in line with our expectations. We delivered a slightly positi
- Globe Newswire
REGISTRATION OF SHARE CAPITAL INCREASE OF 11,577,957 NEW B SHARES COMPLETED
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. Ambu A/S (“Ambu” or the “Company”) has in connection with its accelerated bookbuild offering today registered with
- Globe Newswire
COMPLETION OF DIRECTED ISSUE OF 11,577,957 NEW B SHARES AND 250,000 EXISTING TREASURY B SHARES
Ambu A/S (“Ambu” of the “Company”) has completed its offering of new B shares and existing treasury B shares (together the “Shares”) through an accelerated bookbuilding process (the “Offering”). Further to company announcement no. 6 of 24 March 2023, Ambu has successfully completed an accelerated bookbuild offering of 11,577,957 new B shares and 250,000 existing treasury B shares (in aggregate corresponding to approximately 5.3% of Ambu’s issued B shares), at a sales price of DKK 93 per share, r
- Globe Newswire
CORRECTION: AMBU A/S SEEKS TO STRENGTHEN ITS CAPITAL BASE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. Ambu A/S (“Ambu” or the “Company”) intends to raise approximately 5% of Ambu’s total B shares outstanding through
- Globe Newswire
AMBU A/S SEEKS TO STRENGTHEN ITS CAPITAL BASE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. Ambu A/S (“Ambu” or the “Company”) intends to raise approximately 5% of Ambu’s total B shares outstanding through
- Globe Newswire
AMBU PRESENTS UPDATED MARKET POTENTIAL ASSUMPTIONS AT ITS CAPITAL MARKETS DAY 2023, AND SPECIFIES LONG-TERM FINANCIAL TARGETS
Today, Ambu is hosting a Capital Markets Day. In this context, Ambu will outline its assessment of market potential and dynamics as it expands on its ZOOM IN strategy. This includes innovative solutions and execution, delivering sustainable profitable growth. Ambu maintains FY 2022/2023 financial guidance and specifies its long-term financial targets, which include 5-year organic revenue CAGR, EBIT margin as well as its planned reduction of financial leverage to its target NIBD/EBITDA ratio of l
- Globe Newswire
AMBU CAPITAL MARKETS DAY 2023
Ambu invites institutional investors, analysts and financial media to the company’s Capital Markets Day on Tuesday 21 March 2023. On 21 March 2023, Ambu will host its Capital Markets Day for institutional investors, analysts and financial media, from 10:00-16:00 CET, at the headquarters of Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark. At the event, senior executives from Ambu and external speakers will join Chief Executive Officer, Britt Meelby Jensen, in sharing insights on the company’s
- Globe Newswire
INTERIM REPORT FOR Q1 2022/23
Ambu delivers solid performance for Q1 2022/23. The company posts 4% organic revenue growth for the quarter and continues to progress its new ZOOM IN strategy and global transformation program. Financial guidance maintained for the fiscal year 2022/23, with organic revenue growth at 5-8% and EBIT margin before special items at 3-5%. “In the first quarter of our fiscal year, we rolled out our ZOOM IN strategy across the organisation. The new strategy kicks off a transformation journey for Ambu,
- Globe Newswire
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Attachment 29_11_2022 Thomas F Schmidt
- Globe Newswire
Annual Report 2021/22
Today, Ambu issues the Annual Report for the financial year 2021/22, including Sustainability Report and Remuneration Report. The reports can be found at Ambu.com. Attachments Remuneration Report 2021-22 - Ambu Sustainability Report 2021-2022 - Ambu Ambu-2022-09-30-en Annual Report 2021-22 - Ambu
- Globe Newswire
ANNUAL RESULTS 2021/22 (EARNINGS RELEASE)
Ambu delivered 4% organic revenue growth for the year 2021/22. Global Endoscopy Solutions (previously named Visualisation) revenues grew organically by 1%, mainly driven by strong growth in the ENT (Ear-Nose-Throat) and urology segments, offset by declining sales in the pulmonology segment, mostly due to high Covid-19 comparables. The Anaesthesia and Patient Monitoring businesses posted positive organic growth of 5% and 13%, respectively, driven by pent-up demand and recovery from the Covid-19 p
- Globe Newswire
Ambu A/S: Financial Calendar
This financial calendar lists the expected dates of publication of financial announcements and the Annual General Meeting for the financial year 2022/23. Please see attached PDF. CONTACTS Thomas Frederik Schmidt Chief Financial Officer tfsc@ambu.com / +45 2084 0500Nicolai Thomsen Director, Investor Relations & Strategic Financial Planning nith@ambu.com / +45 2620 8047 Attachment Financial calendar_Company_Announcement_2021_22_no_14
- Globe Newswire
INTERIM REPORT FOR Q3 2021/22
Ambu delivered 8% organic revenue growth in Q3 with 5% organic growth year-to-date. This was driven by a continued rapid uptake of Ambu’s single-use endoscopes within urology and ENT, as well as pent-up demand for Anaesthesia and Patient Monitoring & Diagnostics (PMD) products. The financial outlook from 3 August, 2022 is maintained. Britt Meelby Jensen, Chief Executive Officer of Ambu, says:“For Q3, I am happy to see that we continued to deliver rapid growth in our urology and ENT businesses, w
- Globe Newswire
Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised
Preliminary Q3 organic revenue growth was 8%. Visualization organic growth was 0%, Anaesthesia organic growth was 14%, and Patient Monitoring & Diagnostics (PMD) organic growth was 20%.Current trading for July, the first month of the last quarter of the financial year 2021/22, showed an organic revenue growth of 6%, significantly below expectations.Decision to launch a cost reduction program expected to result in an annualised savings of DKK 250m from the financial year 2022/23. One-off expenses
